TITLE

Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFRtyrosine kinase inhibitor

AUTHOR(S)
Wenxian Wang; Xiaowen Jiang, a; Zhengbo Song; Yiping Zhang
PUB. DATE
January 2016
SOURCE
OncoTargets & Therapy;Jan2016, Vol. 9, p211
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Anaplastic lymphoma kinase (ALK) rearrangement lung cancer responds to ALK tyrosine kinase inhibitors. It is known that many cases ultimately acquired resistance to crizotinib. However, a case of primary resistance is rare. We present a case of harboring exon 19 deletion in epidermal growth factor receptor in ALK rearranged lung adenocarcinoma, who experienced a partial tumor response to icotinib after failure with crizotinib therapy and chemotherapy. Considering the partial response, we conclude that it is important to find the cause of resistance to crizotinib. We detected gene mutations with plasma by the next-generation sequencing; the next-generation sequencing demonstrates an attractive system to identify mutations improving the outcome of patients with a deadly disease.
ACCESSION #
112980439

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics